Skip to main content
Premium Trial:

Request an Annual Quote

Four years and a killer combo


Quick! Got a candle and a cupcake nearby? Well, even if you don’t, help us celebrate our birthday. Believe it or not, Genome Technology’s been around for four years with this issue. As someone who’s been here since the second issue of the magazine came out, I can truly say it is a privilege to be here with you. Thank you all for giving us such a fascinating field and vibrant community to cover.

Speaking of fascinating, take a look at this issue. Like the first genius to pair the unlikely combination of chocolate and peanut butter, scientists in integrated biology have taken the disparate technologies of RNA interference and microarrays and figured out how to make them produce some remarkable results together. Researchers are using these tools together to study off-target effects of RNAi, save money on gene screening experiments, and perform RNAi in a multiplexed, high-throughput fashion. Arrays won’t be the cure-all for the challenges facing RNAi, but they’re certainly making a dent, our experts told us. Check out that story to find out who’s doing what and how far along these technology pairings are.

Ever since the gauntlet was laid down challenging scientists to find innovative ways to cut sequencing costs drastically enough to sequence a human genome for $1,000, we’ve been avidly following the technologies that show some promise of getting there. Last year, we introduced you to 14 efforts underway. In this issue, we revisit the genome-for-a-grand race to bring you a status report. In short, that race is far from over — many experts are predicting five years or more before technology breaks that barrier. Senior Editor John MacNeil takes you on a tour of the field, which in the past year has done much to bring previously academic-only efforts closer to commercialization. There are some new technologies out there, and many of the old favorites are still on track to bring their tools to market.

As you know, next month we’ll be relaunching this magazine. For the most part, we’ll be the same magazine you’re familiar with. But we’ll have a fresh new look thanks to tremendous effort from our art team as well as some new content designed especially for scientists like you who need lots of information as quickly as possible. I’ll save the specifics for next month, but as a hint of what to look for in your mailbox come October, here’s what our new logo will look like. See you next month.


Meredith W. Salisbury, Editor

What do you think of Genome Technology? Let me know how we’re doing by e-mailing me at [email protected] or by calling me at +1.212.651.5635.


Coming in our October issue:

• Centers for integrative genomics: With two new Centers of Excellence in Genomic Science just announced by NHGRI, we’ll take you inside several CEGS to see how they’re doing with their mandate to perform innovative integrative genomics research. The centers’ niches include modeling signal transduction pathways; epigenetics; and new technology development, among others. How will these centers’ efforts help shape the future of genomics and systems biology?

• Quantitative protein analysis: There’s been a surge in the complexity and variety of tools designed to quantify and image which proteins are over- or under-expressed in disease tissue. We’ll look at where the technology has made significant strides, where it is still lacking, and how the data generated may ultimately be of value to life science research.


The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.